Loading clinical trials...

Recombinant Human Relaxin for the Treatment of Decompensated CHF | Clinical Trials | Clareo Health

TERMINATEDPHASE2

Recombinant Human Relaxin for the Treatment of Decompensated CHF

A Phase II Randomized, Double Blind, Placebo-Controlled Study of Recombinant Human Relaxin in Patients With Decompensated Congestive Heart Failure

NCT00406575•Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

View on ClinicalTrials.gov

Summary

Two doses of relaxin will be compared to placebo for the treatment of patients with decompensated CHF

Detailed Description

Pilot clinical data suggest that recombinant human relaxin may be effective in treating patients with decompensated CHF. This study will randomize patients in blinded manner to one of two doses of intravenous relaxin or placebo. Serial evaluations will include cardiac and renal function, as well as safety and tolerability.

Eligibility

Age

19 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Hospitalization
•Decompensated chronic CHF (NYHA Class III-IV)
•LVEF \< 35%
•PCWP \> 22 mmHg
•CI \< 2.3 L/min/m2

Exclusion Criteria

•Acute CHF
•Acute coronary syndrome
•Hypotension or shock
•Recent stroke
•Allergy or sensitivity to test agents
•Significant confounding conditions or medications

Locations (2)

Russian Scientific Centre of Surgery n.a. B.V.Petrovsky of Russian Academy of Medical Sciences

Moscow, Russia

Educational Scientific Medical Center of the General Management Department of the President of Russian Federation. City Clinical Hospital №51

Moscow, Russia

Key Dates

Start Date

November 1, 2006

Primary Completion Date

January 1, 2007

Completion Date

January 1, 2007

Last Updated

May 7, 2014

Enrollment

ACTUAL participants

Conditions

Congestive Heart Failure (CHF)

Interventions

Placebo

DRUG

Recombinant human relaxin (rhRlx)

DRUG

Pulmonary Blood Flow Measurements in CHF Patients

NCT01831713

Congestive Heart Failure (CHF)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 7, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions